Fig. 3: Progression-free survival, overall survival and clinical benefit rate (SD≥ 6 months/PR/CR) according to the high (≥50%) vs. low (<50%) matching scores. | Nature Communications

Fig. 3: Progression-free survival, overall survival and clinical benefit rate (SD≥ 6 months/PR/CR) according to the high (≥50%) vs. low (<50%) matching scores.

From: Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Fig. 3

a Progression-free survival according to the high (≥50%) vs. low (<50%) matching scores (N = 429). Progression-free survival was significantly longer among patients who received therapy with high (≥50%) matching score when compared to patients treated with low (<50%) matching scores. b Overall survival according to the high (≥50%) vs. low (<50%) matching scores (N = 429). Overall survival was significantly longer among patients who received therapy with high (≥50%) Matching Score when compared to patients treated with low (<50%) Matching Scores. c Clinical benefit rate (SD ≥ 6 months/PR/CR) according to the high (≥50%) vs. low (<50%) matching scores (N = 405*). Clinical benefit rate (SD ≥ 6 months/PR/CR) was significantly higher among patients who received therapy with high (≥50%) Matching Score when compared to patients treated with low (<50%) Matching Scores (52.1% vs. 30.3% [P < 0.001]).

Back to article page